Comparative oncology as a tool in drug development requires a deeper examination of the 8 value of the approach and examples of where this approach can satisfy unmet needs. This 9 review seeks to demonstrate types of drug development questions that are best answered 10 by the comparative oncology approach. We believe common perceived risks of the 11 comparative approach relate to uncertainty of how regulatory bodies will prioritize or 12 react to data generated from these unique studies conducted in diseased animals, and how 13 these new data will affect ongoing human clinical trials. We contend that it is reasonable to 14 consider these data as potentially informative and valuable to cancer drug development, 15 but as supplementary to conventional preclinical studies and human clinical trials 16 particularly as they relate to the identification of drug-associated adverse events. 17
Introduction 19
The study of naturally occurring cancer in companion animals, known as comparative 20 oncology, forms the basis of a translational drug development strategy that primarily 21 includes tumor-bearing pet dogs in clinical trials of novel cancer therapies destined for use 22 in human cancer patients.(1-5) The recognition of spontaneous cancer development in 23 2 companion animals, and potential for inclusion of such animals in drug development 24 studies, is based upon observations of canine malignancies that share morphologic, 25 histologic and biologic characteristics with human cancers. Dogs' physical size, amenability 26 to serial biologic sample collections, compressed survival compared to humans, 27 comparable tumor biology, intact immunity and relevant responses to cytotoxic therapies 28 provide clear support to their inclusion as a complementary animal model. (4,5) 29 30 Currently the field of comparative oncology is focused on tumor-bearing dogs as they 31 comprise the majority of those presented to veterinarians for cancer diagnosis and 32 management, which is in turn facilitated by scientific knowledge of malignancies they 33 develop, the collective veterinary clinical experience with anticancer therapies such as 34 chemotherapy and radiation, and availability of basic annotation of the canine genome and within North America to support multicenter clinical trials of investigational therapeutics, 41 wherein centralized trial support and data management is provided by the NCI.(6,7) This 42 mechanism provides access to a clinical trial infrastructure that delivers trial results in a 43 facile manner, considerate of timelines generally required in drug development strategies. 44
Further, a body of published work now exists to demonstrate the feasibility and 45 applicability of the dog cancer model in drug development to ensure data that is both 46 Research. on July 14, 2017. © 2015 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on December 28, 2015; DOI: 10.1158/1078-0432.CCR-15-2347 scientifically sound and robust, thus supporting inclusion into FDA applications. Although 47 not formal FDA guidance, direction for clinical trial conduct and data reporting exists for 48 drugs evaluated in comparative oncology studies in the pre and post-Investigational New 49 Drug (IND) settings, and has been used effectively by groups actively involved in these 50 efforts. (8) 51
Methods 52
Today's challenge is how to best capture and convey the value of these studies, given the 53 timeline for drug development and the diversity of data that collectively informs decisions 54 in the development path. Various attempts at defining value have been made, including a 55 financial model that proposes savings of billions of research and development dollars, 56 achieved primarily through the effective design of better phase II human studies.(9) We 57 propose that the value of the comparative approach lies in the answers to critical drug 58 development questions that are not answered in human trials or conventional preclinical 59 models. Herein we present a summary of the types of questions that are best asked and 60 answered by comparative oncology studies (Table 1) , along with a discussion of selected 61 studies that generated answers to such questions, thus are demonstrative of the value of 62 the comparative oncology approach. 63 biologic activity. This study met all defined objectives, and assisted in devising a dosing 70 strategy to provide prolonged drug exposure to support efficient inhibition of drug target 71 via modulation of a surrogate biomarker in blood (HSP70 upregulation in peripheral blood 72 mononuclear cells (PBMCs)) and tumor levels of c-kit (an HSP90 client protein). 73
Collectively, this data informed the design of human clinical trials of ganetespib and 74 demonstrates the strengths of a naturally-occurring canine model by highlighting the ease 75 of serial biopsy procurement, rapid assessment of differential dose and schedule, and 76 correlative assessment of multiple clinical parameters.(10) In another similar example, an 77 orally-bioavailable XPO1inhibitor verdinexor, a companion agent to a lead human 78 compound KPT-330 (Selinexor, Karyopharm Therapeutics), was studied in tumor-bearing 79 dogs. Based upon profound clinical benefit observed in dogs with non-Hodgkin's lymphoma 80 (NHL) and the marked similarities between canine and human NHL, the data generated 81 What is the clinical response to an investigational agent, and can this response be characterized using standardized, quantitative metrics, including imaging techniques, that are translatable to human clinical studies?
Common criteria employed to communicate tumor responses between veterinary and human patients
35-40
What is the success of an investigational agent in the context of treatment-naïve disease?
Ability to observe responses in patients without preexisting drug resistance as seen in human Phase I
41-45
What is the acute and chronic toxicity profile of an investigational agent, both as a single agent and in combination with conventional chemotherapy? Can this be described with standardized metrics?
Common criteria employed to communicate tumor responses between veterinary and human patients; provide insight into what to expect/monitor for within human patients. 10, 11, 14, 15, 41, 45 Which histologies appear to be most likely to respond to a specific investigational drug or drug class?
Insight into comparable tumor types for study within human patients 10, 11
Pharmacokinetics/Pharmacodynamics
What are the relationships between therapeutic index, demonstration of pharmacodynamics endpoints, and tolerable drug exposure?
Provides supporting data to select a biologically effective dose in conjunction with or instead of an MTD 10, 11, 23, 24, 45
Can PK/PD data obtained in dogs be used to define the optimal dose and schedule of a new drug?
Optimization of dose/schedule prior to prescription of RP2 dose in humans; identification of MTD in dogs 10, 11, 42, 45
Can differential PK/PD relationships within blood vs. tumor be characterized in order to identify which biologic sample is most indicative of PD effect?
Ability to tailor biologic sample collection and correlative assay development for human trials 12 Given a comparable therapeutic index of a given drug between humans and dogs, do therapeutically relevant levels of drug accumulate in tumors at a given (tolerable) dose, schedule and PK profile?
Provides further proof of principle or lack thereof for systemically administered drugs across a range of doses NCI Comparative Oncology Trials Consortium (COTC): A clinical trial of iniparib in tumor-bearing dogs (in press) Drug target investigations Can comparative cancer studies in tumor-bearing dogs identify potential new targets that are druggable in both dogs and humans, and/or identify new molecular signatures that correlate with prognosis?
New candidate genes identified from dog data to support investigations in human patients; shared molecular derangements identified to add comparative relevance to the canine model 15, Can biospecimen repositories be populated with sufficient canine samples to allow matched tissues from primary and metastatic sites within the same patient to allow elucidation of drug targets within the metastatic pathway?
Provides an unparalleled high-quality resource for canine comparative cancer biology investigations
26, 27
Imaging agent validation Can imaging agent performance and validation (target:background ratios, off-target binding, normal biodistribution, lesions distribution kinetics) be assessed in canine cancer patients?
Validated imaging signal against clinical findings and tissue histology; allowed exploration of imaging agent dose and subsequent performance to be validated both in vivo and with ex vivo tissue imaging taken during surgical procedures 17, 39, 47, 48, 49 Can validation of novel imaging agents or feasibility of new imaging protocols be assessed in canine cancer patients?
Allowed exploration of novel combinations of different imaging agents, particularly those with variable radiopharmaceutical composition 17, 50-54
Non-traditional study design
How can a drug's performance in the minimal residual disease (MRD) setting be assessed? Can clinical endpoints that do not involve regression of clinically measurable lesions, rather delay of onset of metastasis, be evaluated?
Provided an opportunity to assess impact on diseasefree interval after removal of a primary tumor with a known high risk of metastatic progression 55 Research. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
